Cited by 691Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Mantovani, Alessandro, Csermely, Alessandro, Petracca, Graziana, Beatrice, Giorgia, Corey, Kathleen E, Simon, Tracey G, Byrne, Christopher D, Targher, Giovanni·2021·The Lancet Gastroenterology & Hepatology

DOI 10.1016/s2468-1253(21)00308-3

Open this paper in CoChat — free account

Abstract

Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with the severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.Methods We systematically searched PubMed, Scopus, and Web of Science from database inception to July 1, 2021, to identify eligible observational studies examining the risk of incident CVD events amongst adult (age ≥18 years) individuals with and without NAFLD and in which NAFLD was diagnosed by imaging, International Classification of Diseases codes, or liver biopsy. The primary outcomes were CVD death, non-fatal CVD events, or both. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on Open Science Framework, number osf.io/5z7gf.Findings We identified 36 longitudinal studies with aggregate data on 5 802 226 middle-aged individuals (mean age 53 years [SD 7]) and 99 668 incident cases of fatal and non-fatal CVD events over a median follow-up of 6·5 years (IQR 5·0-10·2). NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61; I 2=86·18%). This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72; I 2=73·84%). All risks were independent of age, sex, adiposity measures, diabetes, and other common cardiometabolic risk factors. Sensitivity analyses did not modify these results.Interpretation NAFLD is associated with an increased long-term risk of fatal or non-fatal CVD events. CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage. These results provide evidence that NAFLD might be an independent risk factor for CVD morbidity and mortality.Funding None.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(21)00308-3

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Retracted: Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 80
Retracted
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Self-citation
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251

Show all 75 references

Sorted by citations

Items 501–600 of 691

Comparison of structural and functional vascular disorders in patients with comorbidity of non-alcoholic fatty liver disease and two types of arterial hypertension
Prosolenko, K., Molodan, V., Panchenko, G., Lapshyna, K., & Shalimova, A. (2023) · Arterial Hypertension · doi:10.5603/ah.a2023.0008 · Cited by 1
Metabolic syndrome: risks in youth sports
Pavlova, A. A., Klyuchnikov, S. O., Tarasova, M., Feshchenko, V. S., Zholinsky, A. V., & Парастаев, С. А. (2023) · Medicine of Extreme Situations · doi:10.47183/mes.2023.014 · Cited by 1
Non-alcoholic fatty liver disease, cardiovascular system and kidney function in young adults
Чулков, В. С., Pankova, E. D., Krasnopeeva, N., & Сергеевич, Ч. В. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-3-15-21 · Cited by 1
Relationship of cardiac remodeling and perfusion alteration with hepatic lipid metabolism in a prediabetic high fat high sucrose diet female rat model
Jouenne, A., Hamici, K., Varlet, I., Sourdon, J., Daudé, P., Lan, C., Kober, F., Landrier, J., Bernard, M., & Desrois, M. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.089 · Cited by 2
Patients with metabolic dysfunction–associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs
van den Boom, B. P., van Beek, A. P., Adelmeijer, J., Blokzijl, H., & Lisman, T. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102217 · Cited by 1
Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.11.010 · Cited by 1
Atherosclerotic cardiovascular disease in metabolic syndrome
Mitra, S. K., Kanumilli, N., Petroni, M. L., Vora, J. P., & Chaudhury, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00020-7 · Cited by 1
The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today
Smid, V., & Dvořák, K. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.013 · Cited by 2
Bridging Metabolic-Associated Steatotic Liver Disease and Cardiovascular Risk: A Potential Role for Ketogenesis
Carrero, R. S. D. V., Blanco, A., Daimiel, L., Blanco, M. J., Segovia, R. C., de la Garza, R. G., & Martínez‐Urbistondo, D. (2024) · Biomedicines · doi:10.3390/biomedicines12030692 · Cited by 1
Pathogenesis of diabetic atherosclerotic cardiovascular disease
Avogaro, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00019-1 · Cited by 1
Mediating effect of diabetes on the relationship between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease: a prospective cohort study
Wei, Y., Ran, Y., Wang, J., Pei, F., Cui, L., Chen, S., Wu, S., & Zhou, L. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002794 · Cited by 1
Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up
Yu, M., Wu, W., Lin, C., Liu, C., Peng, W., Huang, P., Huang, Y., Hu, J., Chang, H., & Liou, J. (2024) · Hepatology Research · doi:10.1111/hepr.14101 · Cited by 1
Urinary biomarkers of drinking water disinfection byproducts in relation to blood-based liver function parameters among reproductive-aged Chinese women
Gui, P.-P., Deng, Y.-L., Zhang, M., Yu, M., Liu, P., Zeng, J.-Y., Wu, Y. Q., Li, C.-R., Liu, X., Li, Y.-J., et al. (2025) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2025.179016 · Cited by 1
Non-alcoholic fatty liver disease and chronic kidney disease
Туркина, С. В., Андреевна, Т. И., & Титаренко, М. Н. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-49-61 · Cited by 1
Fibrosis-4 index is related to left atrial volume index in patients with acute coronary syndrome
Durak, H. (2025) · Cardiovascular Surgery and Interventions · doi:10.5606/e-cvsi.2025.1789 · Cited by 1
Another arrow in the NASH quiver?
Forlano, R., & Manousou, P. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00383-1 · Cited by 1
Linea guida per la terapia del sovrappeso e dell’obesità resistenti al trattamento comportamentale nella popolazione adulta con comorbilità metaboliche
Chianelli, M., Albanese, A., Carabotti, M., Casarotto, D., Pergola, G. D., Disoteo, O., Grandone, I., Medea, G., Nisoli, E., Raffaelli, M., et al. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01417-8 · Cited by 2
Long-term outcomes in patients with non-alcoholic fatty liver disease: further evidence that a multidisciplinary and patient-centred approach to treatment is needed
Targher, G. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-528 · Cited by 1
Self-citation
A polypill for cardiovascular disease prevention with a focus on non-alcohol steatohepatitis
Joseph, P. G., & Yusuf, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac029 · Cited by 1
Letter to the Editor: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality
Li, Z., Zhang, L., & Li, J. (2023) · Hepatology · doi:10.1097/hep.0000000000000377 · Cited by 1
Editorial: MTTP, hepatic steatosis and plasma lipids – still more questions than answers
Chen, V. L. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17611 · Cited by 1
Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2248242 · Cited by 1
Self-citation
Towards a broader perspective on non-alcoholic fatty liver disease and coronary artery disease relationship: managing metabolic risk beyond genetics
Corica, B., & Proietti, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf004 · Cited by 1
Monocyte CD14 changes and endotoxemia after major hepatectomy.
KOMATSU, S., Moriwaki, Y., Togo, S., Kurosawa, H., & Shimada, H. (2001) · PubMed
Evaluation of Coronary Artery Disease Among Patients with Non-Alcoholic Fatty Liver Diseases Using Multislice C.T.
RASHAD, M. D. A. M. O. A. M., & MARIE, M. S. M. A. (2022) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2022.239613
Screening for advanced liver fibrosis in overweight and obese patients with NAFLD
Stefan, N. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.29
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
NASH et chirurgie de l’obésité
Leray, M., Lassailly, G., & Pattou, F. N. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.12.002
Editorial: MTTP , hepatic steatosis, and plasma lipids—still more questions than answers. Authors' reply
Hehl, L., Schneider, C. V., & Rader, D. J. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17624
Pathophysiology and Risk Stratification in Cardiovascular Diseases and NAFLD
Gîrleanu, I., & Chiriac, S. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_13
Linear age-course association between non-alcoholic fatty liver disease, components of metabolic syndrome, and mortalityPreprint
Zhao, X., Chen, S., Wang, X., Wang, Z., Sun, Y., Yang, C., Zheng, M., Wang, Y., Liao, W., Wu, S., et al. (2023) · medRxiv · doi:10.1101/2023.08.01.23293528
Reply to: “Reassessing the causal relationship between liver diseases and cardiovascular outcomes” and “From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank”
Thomaides-Brears, H. B., Banerjee, R., & Banerjee, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.037
Current Status of Research on Cardiovascular Risk in Patients with Non-Alcoholic Fatty Liver Disease
娜迪热, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112445
Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Disease: Pathophysiological Mechanisms
范, 家. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143861
PREDICTIVE VALUE OF FIBROSIS-4 INDEX FOR HIGHER TROPONIN LEVELS IN ACUTE CORONARY SYNDROME
Durak, H., & Ergül, E. (2024) · Kırıkkale Üniversitesi Tıp Fakültesi Dergisi · doi:10.24938/kutfd.1400280
Association between Nonalcoholic Fatty Liver Disease on CT and Myocardial Infarct Size using SPECT-MPI in patients with ST-elevation Myocardial InfarctionPreprint
Cui, W., Li, N., Gao, X. L., Liu, X., Bai, Q., Li, Z., Zhou, Z., Yu, H., Yu, L., Li, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4357262/v1
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Nonalcoholic fatty liver disease–related extrahepatic complications, associated outcomes, and their treatment considerations
Oh, J. H., & Jun, D. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00007-8
METABOLICALLY ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK: PREVALENCE, CLINICAL SIGNIFICANCE, GENDER DIFFERENCES
Korolyuk, O. Y., Komarytsia, O. Y., Huk-Leshnevska, Z., & Zenin, V. (2024) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2024;12(2):278-293
La sfida della prevenzione in medicina interna: a call for action | The challenge of prevention in internal medicine: a call for action
Dentali, F., & Rotunno, S. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.q.2024.4
Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease
Li, Q. I. N., JunRu, W. U., YuQing, L. I. U., YingXuan, G. O. N. G., & JingJing, C. A. I. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0098
The liver in pediatric obesity : risks and consequences of increased transaminases and steatotic liver disease
Putri, R. R. (2024) · doi:10.69622/26988703
Fatty liver disease: An updated overview of risk factors
Alsayegh, A. S., Alduaybi, M. A., Alanizi, H. G., Alajmi, N. A. A., Saeed, S. M. B., Owias, M. I. Z. A., Rashedi, A. A. A., Alqahtani, A. S., & Alanezi, B. S. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.15308
Topics on MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease)
Kawanaka, M. (2024) · Health Evaluation and Promotion · doi:10.7143/jhep.51.531
Fibrosis-4 index is closely associated with future development of hypertension in the Japanese general population
Yamashita, S., Takase, H., Kawakatsu, N., Hayashi, K., Kin, F., Isogaki, T., & Dohi, Y. (2024) · Hypertension Research · doi:10.1038/s41440-024-02028-4
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69
Clinically Accessible Liver Fibrosis Association with CT Scan Coronary Artery Disease Beyond Other Validated Risk Predictors: The ICAP Experience
Izquierdo, B. G., Martínez‐Urbistondo, D., Guadalix, S., Pastrana, M., Buenestado, A. B., Colina, I., de Yébenes, M. G., Bastarrika, G., Páramo, J. A., & Delgado, J. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041218 · Cited by 1
Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression
Jönsson, C., Ma’ayeh, S. Y., Zhang, B., Kechagias, S., Liljeblad, M., Nasr, P., Hansson, S., & Ekstedt, M. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110920
WITHDRAWN: Association between NAFLD and Myocardial Infarct Size in Patients with STEMI: A cross-sectional Study and Bioinformatics Analysis based on the GEO Database
Cui, W., Li, N., Gao, X. L., Liu, X., Bai, Q., Li, Z., Zhou, Z., Yu, H., Yu, L., Li, C., et al. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200396
Retracted
Identification of a Risk-Prediction Model for Hypertension Patients Concomitant with Nonalcoholic Fatty Liver Disease
Mai, X., Li, M., Jin, X., Huang, S., Xu, M., Yan, B., Wei, Y., Long, X., Wu, Y., & Mo, Z. (2025) · Healthcare · doi:10.3390/healthcare13090969
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
Sharma, A. R., & Barb, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_10
Nonlinear relationship between serum high sensitivity C reactive protein to high density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease
Xuan, Y., Wang, B., Xie, B., Cen, Y., Yu, S., & Yao, Q. Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-03528-0 · Cited by 1
Validation of the FibroScan-AST (FAST) and Agile 3+ score in metabolic dysfunction-associated steatotic liver disease in a Russian cohort of patients
Павловна, Г. В., Raikhelson, K. L., Кащенко, В. А., Lodygin, A. V., & Karev, V. E. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-218
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Association of hepatic steatosis and fibrosis with 10-year estimated cardiovascular disease risk in hypertensive patients and the mediating role of triglyceride-glucose indexPreprint
Yin, Y., & Shi, L. (2025) · Research Square · doi:10.21203/rs.3.rs-6894190/v1
Detection of masked hypertension in patients with metabolic-dysfunction associated steatotic liver disease using a novel clinical risk model
Kasper, P., Demir, M., & Steffen, H. (2025) · Journal of Human Hypertension · doi:10.1038/s41371-025-01047-z
Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Khoury, S. E., Harake, S. N. A., Youssef, T., Risk, C. E., Helou, N., Doumet, N. M., Aramouni, K., Azar, S. T., Najjar, S. M., & Ghadieh, H. E. (2025) · Livers · doi:10.3390/livers5030034
Comment on: exploring the correlation between high-risk coronary plaque and hepatic fat fraction in nonalcoholic fatty liver disease (NAFLD) using spectral computed tomography (CT)
Köker, G., & Durmus, E. (2025) · Clinical Radiology · doi:10.1016/j.crad.2025.107037
Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
Zhou, X., Yilmaz, Y. N., & Zheng, M. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70337
Efficacy of digital-based exercise intervention in adults with metabolic associated fatty liver disease: study protocol for a randomised controlled trial in Nanjing, China
Xia, N., Cheng, Y., Liu, J., Li, D., Li, J., Li, H., Meng, F., Zhu, Y., & Qin, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095151
Association between Life’s Essential 8 and liver fibrosis: NHANES 2017-2018
Yang, J., & Qi, F. (2025) · Nutrición Hospitalaria · doi:10.20960/nh.05710
Operational merit of Controlled Attenuation Parameter and Liver Stiffness Measurement across grades of Metabolic Dysfunctional Associated Steatotic Liver Disease: A cross-sectional studyPreprint
Sujina, S. S., Manjrekar, P., Rao, R., Tantry, B. V., Rai, S., Ashok, D., & Hegde, A. (2025) · medRxiv · doi:10.1101/2025.09.28.25336846
Hyperuricemia affects long-term prognosis in metabolic dysfunction–associated steatotic liver disease: a multinational study
Ye, J., He, J., Gong, X., Li, X., & Zhong, B. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104410
Mechanistic Links Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction in a Mouse ModelPreprint
Rweished, N., Rokach, Y., Parnasa, E., Abedat, S., Bsoul, A., Nachman, D., Amir, O., Safadi, R., & Asleh, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.02.686066
Statins and the Cardio-Hepatic Axis: Balancing Cardiovascular Protection with Liver Disease Safety
Alkasabrah, O. Y., Joshi, D. K., Hafeez, A., Agrawal, S. P., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001122
Non-invasive liver fibrosis scores and mortality in a cohort of World Trade Center rescue/recovery workers
Singh, A., Zeig‐Owens, R., Icitovic, N., Goldfarb, D. G., Hall, C. B., Choi, J., Dasaro, C. R., Garrity, V., Todd, A. C., & Prezant, D. J. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001889
Severity of Non-Alcoholic Fatty Liver Disease Assessed by FibroScan in Patients With and Without Ischemic Heart Disease: A Cross-Sectional Study
Shaikh, K., Karim, S., Ahmed, N., Basit, A., Batool, N., & Kaleem, F. (2025) · Cureus · doi:10.7759/cureus.97927
Quantitative evaluation of myocardial work in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver by noninvasive pressure-strain loop
Tian, M., Hou, X., Wang, Z., Cui, X., Meng, J., Ren, X., Ping, W., Li, K., & Wang, X. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05381-5
Liver fibrosis and diabetic peripheral neuropathy in individuals with type 2 diabetes mellitus: an observational, cross-sectional study
Zanni, E., Coluccia, S., Boni, S., Colzani, M., Sueri, R., Lugari, S., Felicani, C., Nascimbeni, F., & Greco, C. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.89
Additional file 1 of Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study
Xin, Z., Huang, J., Cao, Q., Wang, J., He, R., Hou, T., Ding, Y., Lu, J., Wang, T., Zhao, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26574271
Additional file 1 of Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study
Zhou, B.-G., Xia, J., Jiang, X., Ding, Y.-B., & She, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25440968
Additional file 1 of Association of sugar intake from different sources with cardiovascular disease incidence in the prospective cohort of UK Biobank participants
Schaefer, S. M., Kaiser, A., Eichner, G., & Faßhauer, M. (2024) · Figshare · doi:10.6084/m9.figshare.25264394
Additional file 1 of Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study
Garofolo, M., Lucchesi, D., GIAMBALVO, M., Aragona, M., Bertolotto, A., Fabrizio, C., Bianchi, C., Francesconi, P., Marchetti, P., Del Prato, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26686872
Additional file 1 of Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
Mantovani, A., Morieri, M. L., Palmisano, L., Masulli, M., Cossu, E., Baroni, M. G., Bonomo, K., Cimini, F. A., Cavallo, G., Phd, R. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26609649
Self-citation
Additional file 1 of Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lu, Q., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24580347
Additional file 1 of Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Figshare · doi:10.6084/m9.figshare.27012178
Competing Cardiometabolic Pathways of Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease
Hirooka, M., Miyake, T., Yano, R., Nakamura, Y., Okazaki, Y., Shimamoto, T., Yukimoto, A., Yamamoto, Y., Watanabe, T., Yoshida, O., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100882
Cross-sectional analysis of adult fatty liver prevalence in Wenshan, China: an epidemiologic study using ultrasound and laboratory assessments
Zeng, G., Li, G., Lin, X., Shoude, Y. A. N. G., & Zeng, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1571261
Association between MASLD and risk of ASCVD in IBD patients: A systematic review and Meta – Analysis
Rahadini, A. A. D., Rahadina, A., & Widodo, B. (2026) · Perinatal Journal · doi:10.57239/prn.26.034100128
Fatty liver index as a predictor of fatal and non-fatal cardiovascular events in Russians: analysis of an epidemiological cohort
Евстифеева, С. Е., Shalnova, S. A., Kutsenko, V. A., Владимировна, К. А., Аркадьевна, М. Г., Balanova, Y. А., Имаева, А. Э., Karamnova, N. S., Kotova, M. B., Maksimov, S. A., et al. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2025-4589
Dyslipidemia and Hypertension as Independent Risk Factors for Non-Alcoholic Steatohepatitis: A Matched Case-Control Study from QatarPreprint
Khinji, A. A., Malouche, D., Al-Thani, N., Mustafa, A., Abdulmajeed, J., & Al‐Kuwari, M. G. (2026) · Research Square · doi:10.21203/rs.3.rs-8594404/v1
Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
Komaki, S., Nakai, M., Matsuura, Y., Yamamoto, K., Tanaka, H., Komaki, Y., Yamaguchi, M., Moribayashi, K., Ideguchi, T., Kawakami, H., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70250
Sex-Specific Basal Metabolic Rate and NAFLD Risk: The Multi-Population Observational and Mendelian Randomization Study
Hu, C., Tao, Y., Zhang, L., Cheng, Z., Sun, L., & Chen, Z. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s583771
Risk factors and surrogate indicators for cardiovascular disease are prevalent in Common Variable Immunodeficiency and associate with inflammatory phenotype
Yu, A. J. S., Moreira, F., Symes, A., Curlewis, K., O’Sullivan, M., Jayasundera, J., Rhermoul, F.-Z. E., Lever, C., Stoenchev, K. V., Chow, K. L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1756049
Steatotic liver disease indices for cardiovascular event prediction: Panasonic cohort study 28
Kuramoto, N., Okada, H., Nakajima, H., Nakanishi, N., Ushigome, E., Hamaguchi, M., Ohkuma, T., Tanaka, D., Miyake, T., Kurogi, K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101541
Association between blood selenium level and nonalcoholic fatty liver disease among naturally menopausal women: A cross-sectional study
Chen, C., Yu, Y., Hu, J., Zheng, G., Li, J., Xie, C., Wang, Z., Chen, X., Zheng, M., Liang, C., et al. (2026) · Medicine · doi:10.1097/md.0000000000048008
From Policy to Practice: Knowledge gaps and training outcomes related to MASLD guidelines among medical officers in Chhattisgarh, India
Kaushal, K., Aggarwal, P., Saifi, G., Mhatre, S., Kumar, G., Jain, S., Shah, U. K. P., Gautam, S., & Sarin, S. K. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14169-y
The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists
Abdou, H. A., & Omar, S. A. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.031826446
Quality Oriented Insights from Large-scale Bibliometric Analysis of Industrial 3D Printing: The S3DEF FrameworkPreprint
Goel, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9113003/v1
Letter to the editor: Dynamic FIB-4 trajectory and a multi-state markov model analysis reveal fibrosis progression and cardiovascular-cerebrovascular risk in MAFLD patients
Baharuddin, B., Handayani, L., Ikawaty, R., & Akl, M. M. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104720
IMPACT OF S-ADENOSYLMETHIONINE ON NITRIC OXIDE SYSTEM PARAMETERS IN PATIENTS WITH METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE AND CONCOMITANT ISCHEMIC HEART DISEASE
Ohanisyan, E. V., Skrypnyk, I. M., Maslova, G. S., & Pilat, I. O. (2026) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.26.1.68
Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125
Effect of nonalcoholic fatty liver disease on post-myocardial infarction cardiac remodeling
Biquard, L. (2022) · theses.fr (ABES) · doi:10.70675/4f4848d2z6a02z4576z9fc3zff58e2f5c501
Pathophysiologie der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung
Kantartzis, K. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01459-6
Sleeve Gastrectomy Alters Exosomal miR-497-5p Cargo to Ameliorate Metabolic Dysfunction–Associated Steatotic Liver by Targeting GABARAPL1
Li, Z., Tian, C., Wang, M., Li, Z., Wang, L., Zheng, W., Yu, C., Wang, D., Lian, D., & Zhang, N. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s568182
Metabolic dysfunction-associated fatty liver disease and cardiac remodeling in non-ischemic dilated cardiomyopathy
Wang, J., Fang, X., Liang, Y., He, Q., Li, Y., Li, D., Fang, X., & Liu, Y. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104752
Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Cho, Y. K., Park, H., Lim, T. S., Jhee, J. H., & Jhee, J. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70792
Reimbursement restrictions reduce liver fibrosis screening in adults with diabetes in Ontario: a population-based interrupted time series analysis
Burnside, J., Djerboua, M., Flemming, J. A., Sebastiani, G., Wong, W. W. L., Lu, Z., BAJAJ, H. S., Patel, K., Biondi, M., Betel, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-48600-5
Response to correspondence: MASLD and revascularized coronary events: a cautious reading of the data
Kang, H. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120751
MASLD and revascularized coronary events: a cautious reading of the data
Koulaouzidis, A., Marlicz, W., & Koulaouzidis, G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120750

Authors: Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G.
Affiliations: University of Verona (IT)
Harvard University (US)
Southampton General Hospital (GB)
Corresponding author: Targher, Giovanni
ORCID: Mantovani, Alessandro
Csermely, Alessandro
Corey, Kathleen E
Simon, Tracey G
Byrne, Christopher D
Targher, Giovanni
Venue: The Lancet Gastroenterology & Hepatology
Publisher: Elsevier BV
Published: 2021-11
Volume: 6
Issue: 11
Pages: 903-913
ISSN: 2468-1156 (ISSN-L)
2468-1253
DOI: 10.1016/s2468-1253(21)00308-3
OpenAlex: W3201276384
Cited by: 674
References: 75
Citations by year: 2026: 160 · 2025: 151 · 2024: 141 · 2023: 122 · 2022: 95 · 2021: 4
FWCI: 13.85
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: The Lancet. Gastroenterology & hepatology (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (acceptedVersion)
Funders: National Institute for Health Research Southampton Biomedical Research Centre (IS-BRC-20004)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular mortality, cardiovascular events, liver fibrosis, disease severity, cardiometabolic risk factors, cardiovascular risk factors, middle-aged adults, NAFLD staging
MeSH terms: Cardiovascular Diseases, Humans, Risk Factors, Severity of Illness Index, Models, Statistical, Survival Analysis, Observational Studies as Topic, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks